ORPHELIA Pharma awarded a grant from the region Île-de-France to support business activity development in Europe and in the US
Paris and Lyon, January 26th, 2021. ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric and orphan drugs announces today that it has received the support from the region Île-de-France as part of the PM’up program to accelerate the development of the company in Europe and the US. ORPHELIA Pharma will receive a grant of 250 000 € aimed at supporting the international development of the company.
“We are grateful to receive the support from region Île-de-France which will allow us to accelerate the development of our medicines portfolio worldwide. Our products address unmet medical needs of life-threatening paediatric diseases and our ambition is to make them available to all patients“, comments Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma.
“We will use the proceeds to implement the marketing operations of Kigabeq® in Europe and continue the efforts in finding partners for key territories elsewhere“, states Hugues Bienaymé, General Manager. “This program will also support the preparation of the US dossier and the evaluation of the market access strategy of Kimozo®, the first paediatric drinkable formulation of temozolomide currently under development for the treatment of relapsed or refractory neuroblastoma”, he adds.
About PM’Up program
The Région Ile-de-France supports the development of Small and Medium-sized Enterprises by providing financial assistance to support their growth strategy. PM’up is a grant of up to 250 000 € to finance a 3-year development plan. For more information, please visit https://www.iledefrance.fr/pmup.
About ORPHELIA Pharma
ORPHELIA Pharma is a biopharmaceutical company based in Paris and Lyon that develops and markets drugs for the treatment of paediatric and rare diseases.
Our mission is to provide patients with essential hospital products in the fields of epilepsy and oncology with formulations adapted to the paediatric population. Our first product, Kigabeq®, received European marketing authorisation in September 2018 and is being launched in several countries. Our second product, Ivozall®, obtained European marketing authorisation in November 2019 for the treatment of acute lymphoblastic leukaemia. ORPHELIA Pharma conducts research projects through academic and industrial collaborations.